FDA adcomm shoots down Capricor’s Duchenne cell therapy after meeting marked by statistical dispute

A panel of experts today voted against Capricor’s cell therapy for Duchenne muscular dystrophy, capping off an advisory committee meeting marked by statistical confusion.